Alkem Laboratories Launches NeuCeno in India: New Epilepsy Treatment for Adult Seizures
Alkem Laboratories has launched NeuCeno (cenobamate) in India for adult partial-onset seizures. The once-daily oral therapy showed up to a 78 per cent seizure reduction in clinical trials. Notably, NeuCeno is a once-daily oral therapy available in strengths ranging from 12.5 mg to 200 mg tablets. Scroll below to know more.
Alkem Laboratories has announced the official launch of NeuCeno, containing cenobamate, for the treatment of partial-onset seizures in adult patients. The medication marks the first time cenobamate is being made available in India, introducing a new therapeutic option for a country where an estimated 94 lakh people live with epilepsy.
NeuCeno is structured as a once-daily oral therapy, with tablets available in strengths ranging from 12.5 mg to 200 mg. Adult Epilepsy Treatment May Work for Children Too, Says Study.
Clinical Efficacy and Seizure Management
In clinical studies involving adult patients with uncontrolled focal seizures despite existing medications, adjunctive treatment with cenobamate demonstrated substantial reductions in seizure frequency. According to exchange filings, the therapy showed up to a 78 per cent reduction in seizure frequency, with up to 30 per cent of patients achieving complete seizure freedom during the maintenance phase.
NeuCeno Marks a Step Forward in Treating Partial-Onset Seizures in Adults
9.4 million Indians live with epilepsy. Alkem's newly launched NeuCeno (cenobamate) marks a step forward in treating partial-onset seizures in adults.
Read more: https://t.co/s0mqzZo3xc#ProductLaunch #AlkemLaunch #AntiSeizureMedication #InspiringHealthierLives pic.twitter.com/ctlJe70hU4
— Alkem Laboratories Ltd. (@Alkem_Lab) September 16, 2026
Highlighting the impact of the new rollout, Sandeep Singh, Managing Director of Alkem Laboratories, stated, "People living with epilepsy and their caregivers face significant challenges in achieving effective seizure control. Cenobamate has the potential to transform treatment outcomes towards delivering better epilepsy management.”
Market Context and Public Health Impact
The introduction of NeuCeno addresses a critical therapeutic need in India's neurology sector, where managing drug-resistant focal seizures remains a primary hurdle for clinicians and patients. By providing a once-daily oral dosage regimen across flexible strength tiers, Alkem Laboratories aims to streamline adherence and enhance long-term seizure control for millions of adults nationwide.
(The above story first appeared on LatestLY on Sep 16, 2026 11:18 PM IST. For more news and updates on politics, world, sports, entertainment and lifestyle, log on to our website latestly.com).
